Comparative Pharmacology
Head-to-head clinical analysis: OZURDEX versus PREDSULFAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OZURDEX versus PREDSULFAIR.
OZURDEX vs PREDSULFAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone, a potent corticosteroid, reduces inflammation by inhibiting multiple inflammatory cytokines including prostaglandins, leukotrienes, and interleukins. It suppresses the migration of polymorphonuclear leukocytes and reverses increased capillary permeability. The mechanism involves binding to the glucocorticoid receptor, leading to regulation of gene expression that reduces production of inflammatory mediators.
PREDSULFAIR is a combination of prednisolone (corticosteroid) and sulfacetamide (sulfonamide antibiotic). Prednisolone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis. Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking folate synthesis.
Single intravitreal implant of 0.7 mg (dexamethasone 700 mcg) in the affected eye; repeat dosing no sooner than 3 months after the prior implant.
Prednisolone 0.5-1 mg/kg orally once daily, maximum 60 mg/day; Sulfasalazine 500 mg orally twice daily, increased by 500 mg weekly to maintenance 2-3 g/day in divided doses.
None Documented
None Documented
In the vitreous humor, the half-life is approximately 5-7 months following intravitreal implant administration. Systemic half-life is negligible due to low systemic exposure.
Prednisolone: 2.1–3.5 hours (plasma); biological half-life 12–36 hours (duration of HPA axis suppression). Sulfafurazole: 3–6 hours (normal renal function), prolonged to 12–24 hours in renal impairment.
Primarily hepatic metabolism via CYP3A4; metabolites excreted in feces (≈70%) and urine (≈30%). Less than 1% excreted as unchanged drug.
PREDSULFAIR is a fixed-dose combination of prednisolone and sulfafurazole. Prednisolone is primarily metabolized hepatically; inactive metabolites are excreted renally (<30% unchanged). Sulfafurazole is acetylated and glucuronidated; parent drug and metabolites are excreted renally (≥90%, with 15-30% unchanged). Biliary/fecal elimination is minimal for both components (<5%).
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid/Sulfonamide Combination